Emmaus Life Sciences (Formerly Known As Emmaus Medical, Inc.)
3870 Del Amo Boulevard
103 articles with Emmaus Life Sciences (Formerly Known As Emmaus Medical, Inc.)
Emmaus, a Leader in Sickle Cell Disease Treatment, Signs Agreement with McKesson to Expand Distribution Network for Endari™ (L-glutamine oral powder)
Emmaus Life Sciences, Inc. (Emmaus), announces it has entered into a distribution agreement with McKesson Plasma and Biologics LLC (McKesson)
Bill Aims to Improve Understanding of Health Care System Utilization for Patients with SCD
Emmaus Life Sciences Partners with DMS Pharmaceutical Group to Provide Endari™ (L-glutamine oral powder) to Military Personnel and Beneficiaries for Treatment of Sickle Cell Disease
Emmaus Life Sciences (Emmaus) announces it has entered into a distribution agreement with DMS Pharmaceutical Group (DMS).
Emmaus Life Sciences Strengthens its Finance & Operations Leadership to Support Commercialization of Endari™
Adds Kurt Kruger as CFO; Daniel Frey as Controller
Emmaus Life Sciences Announces the New England Journal of Medicine has Published the Phase 3 Trial Results of Endari™ (L-Glutamine Oral Powder) in Sickle Cell Disease
Results showed a significant improvement in these measures: lower median number of sickle cell crises, fewer hospitalizations, lower cumulative days in hospital, and lower incidence of acute chest syndrome
Emmaus Life Sciences Announces FDA Acceptance of IND Application for Clinical Study of L-glutamine for Treatment of Diverticulosis
Emmaus Life Sciences today announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for L-glutamine as a treatment for diverticulosis.
Collaboration will expand patient education, strengthen community-based organizations and increase national awareness efforts
Emmaus Life Sciences (Emmaus) announced today it has opened an office in Midtown Manhattan to support the commercial launch of EndariTM (L-glutamine oral powder).
Emmaus Life Sciences Receives Validation From European Medicines Agency on Marketing Authorization Application for Sickle Cell Disease Treatment Xyndari (oral glutamine)
Sickle cell disease patients in the European Union have not had access to new therapies for almost 20 years.
Emmaus Life Sciences Announces Medicaid Coverage of Endari (L-glutamine oral powder) for Sickle Cell Disease in the United States
Emmaus Life Sciences announced today that it has a Medicaid Drug Rebate Agreement with the Centers for Medicare & Medicaid Services allowing coverage of Endari (L-glutamine oral powder) to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
Proceeds from the investment will help Emmaus commercially launch Endari which was approved in 2017 by the FDA.
Emmaus Life Sciences Announces Availability of Endari (L-glutamine oral powder) for Sickle Cell Disease in the United States
Endari was approved by the FDA to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.
Emmaus Life Sciences Sickle Cell Treatment Receives Positive Opinion on Pediatric Investigation Plan from European Medicines Agency
Emmaus Life Sciences announced today that the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) has accepted the company's pediatric investigation plan (PIP) for its treatment of sickle cell disease.
An administrative matter is causing a minor delay in its release; however, Emmaus is committed to providing Endari to patients as soon as possible and the date of availability will be announced in the near term.
Generex Biotechnology Corporation Provides Update On Deal To Acquire Controlling Equity Interest In Emmaus Life Sciences
Emmaus Life Sciences Receives Notice Of Allowance For Japanese Patent For Use Of L-Glutamine In Treatment Of Diabetes
Emmaus Life Sciences Receives Notice Of Allowance For U.S. Patent For Use Of L-Glutamine In Treatment Of Diverticulosis